Richmond Pharmacology is proud to announce that its clinical trial volunteers recognise the value of the research they contribute to. The results come from recent internal polling conducted by the organisation.

The poll of 217 local volunteers, drawn from Croydon and surrounding areas, showed that over 90% were happy to continue their relationship with Richmond. Volunteers currently help to develop new medicines for some of the biggest killers, including cancer, lung disease and diabetes.

Among reasons given for their involvement, nearly a quarter of volunteers said that they had benefitted from either learning more about their medical status or enjoying the experience of the study.

Staff members were also singled out for praise. One respondent praised the some 100 local staff that work at Richmond, saying there was great team morale and the patients don't feel strange to be in a hospital and do the clinical trial.

Richmond's globally recognised clinical research facility has been based at Croydon University Hospital since 2005. Over 60% of respondents also felt that having a clinical research organisation like Richmond was beneficial to both the hospital and the local area.

Dr Jorg Taubel, founder and CEO of Richmond Pharmacology said I'm delighted by these results. Healthy volunteers and patients are the heart of what we do and I'm glad that so many want to continue contributing to the development of better and much needed novel medicines.

�We have been working closely with the people of Croydon for eight years and I'm proud that these volunteers recognize our contribution to Croydon's main hospital and the contribution we make towards the regeneration of the local area.�

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event